Next Article in Journal
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
Next Article in Special Issue
Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold
Previous Article in Journal
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
Previous Article in Special Issue
Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview
Article Menu

Export Article

Open AccessReview
Biomedicines 2016, 4(3), 14; doi:10.3390/biomedicines4030014

Antibody–Drug Conjugates for Cancer Therapy

1
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia
2
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia
3
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria 3084, Australia
4
Department of Medicine, University of Melbourne, Melbourne 3010, Australia
5
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria 3084, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Michael A. Firer
Received: 10 May 2016 / Revised: 24 June 2016 / Accepted: 27 June 2016 / Published: 11 July 2016
View Full-Text   |   Download PDF [1024 KB, uploaded 11 July 2016]   |  

Abstract

Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. View Full-Text
Keywords: ADC; antibody–drug conjugate; resistance; monoclonal antibodies; cancer; immunotherapy ADC; antibody–drug conjugate; resistance; monoclonal antibodies; cancer; immunotherapy
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Parslow, A.C.; Parakh, S.; Lee, F.-T.; Gan, H.K.; Scott, A.M. Antibody–Drug Conjugates for Cancer Therapy. Biomedicines 2016, 4, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top